TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Cord Blood America Names Business Development Director (PR Newswire) Cord Blood America, Inc. , the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, announced today that Lea Ann Stiller, whose daughter's life was saved with the first collection of umbilical cord blood stem cells for a bone marrow transplant, has been named Director of Business Development for the Company. us.rd.yahoo.com |
Cadus Corporation: Less a Company Than a Publicly Traded Checking Account - WSJ Greenbackd submits: In September last year I picked up a small position in Cadus Corporation (OTC: KDUS.OB). The idea was as follows: Cadus Corporation is an interesting play, but not without hairs on it. First, the good news: It’s trading at a discount to net cash with Carl Icahn disclosing an activist holding in 2002, and Moab Capital Partners disclosing an activist holding more recently. At its $1.51 close yesterday, the company has a market capitalization of $19.9M. The valuation is straight-forward. We estimate the net cash value to be around $20.6M or $1.57 per share and the liquidation value to be around $23.2M or $1.77 per share. The liquidation value excludes the potential value of federal and New York State and City net operating loss carry-forwards. It’s not a huge upside but it’s reasonably certain, and we think that’s a good thing in this market. The problem with the position is the catalyst. It’s a relatively tiny position for Icahn, so he’s got no real incentive to do anything with it. He’s been in the position since 2002, so he’s clearly in no hurry. That said, he’s not ignoring the position. He last updated his 13D filing in March this year, disclosing an increased 40% stake. He’s also got Moab Capital Partners to contend with. Moab holds 9.8% of the stock and says that it “has had good interaction with the CEO of Cadus, David Blitz, and feels comfortable that he will structure a transaction with an operating business that will generate significant long-term value for Cadus holders.” KDUS could end up being a classic value trap, but we think it’s worth a look at a discount to net cash, and two interested shareholders.Complete Story » seekingalpha.com |
Cord Blood America Says Two Recent Financial Transactions Strengthen Company's Balance Sheet (PR Newswire) Cord Blood America, Inc. , the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today said that it has had positive movement on two financial obligations that further strengthen its balance sheet. us.rd.yahoo.com |
J&J Is Faulted on Recall Timing Johnson & Johnson should have moved sooner to recall some Motrin pills that it discovered were defective in late 2008, a federal official said in prepared testimony. online.wsj.com |
Abbott Laboratories Management Discusses Q3 2010 Results – Earnings Call Transcript Abbott Laboratories (ABT)Q3 2010 Earnings Call TranscriptOctober 20, 2010 9:00 am ETComplete Story » seekingalpha.com |